Analysis of tumor-infiltrating T cells revealed marked increases in IFN-γ production in both the CD4+ and CD8+ subsets in this treatment group, suggesting that VISTA blockade may prime T cells to be more effectively activated by a tumor vaccine5. The gene discussed is CD8A; the disease is neoplasm.